Fact CheckerSign in

NCT07802912Completed

Efficacy of Traditional Integrated Islamic Psychotherapy and Cognitive Behavioural Therapy for Migraine: A Randomized Controlled Trial

Source: ClinicalTrials.gov · Last updated 3 Sept 2026

Brief summary (registry, in English)

his randomized controlled trial aims to evaluate the efficacy of Cognitive Behavioral Therapy (CBT) and Traditional Integrated Islamic Psychotherapy (TIIP) as psychological interventions for individuals with chronic migraine. The study will compare the effects of CBT and TIIP with a medication-only control group on migraine-related disability, headache management self-efficacy, psychological distress, and quality of life.

Status (registry)
Completed
Study type
Interventional
Enrollment
45 (actual)
First submitted
31 Aug 2026
Start date
10 Mar 2025
Primary completion date
20 Jun 2026
Lead sponsor
GIFT University
Diseases
Migraine
NCT number
NCT07802912

What you commit to

  • Study type: Interventional
  • Participants enrolled: 45
  • From 10 Mar 2025 to the primary completion date, 20 Jun 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Concurrent psychotherapy or enrolment in another intervention study.

Other illness

  • A diagnosed severe psychiatric disorder, including psychotic disorder, bipolar disorder, or severe major depressive disorder with active suicidality.
  • A current need for intensive or immediate psychiatric treatment.
  • A substance use disorder within the preceding six months. Substance use and withdrawal are themselves recognised causes of headache under the International Classification of Headache Disorders (Headache Classification Committee of the International Headache Society, 2018) and independently raise scores on measures of depression, anxiety, and stress, so their inclusion would have confounded both the primary and the secondary outcomes. Six months was adopted because it maps onto the early remission specifier of the DSM-5-TR, under which someone who has met no criterion for a substance use disorder for at least three months but less than twelve is classified as in early remission (American Psychiatric Association, 2022), making it a recognised diagnostic boundary rather than an arbitrary line.
  • A neurological disorder other than migraine, such as epilepsy, brain tumour, or multiple sclerosis.
  • A serious medical condition likely to interfere with participation or to confound the outcomes.

Age

  • Aged below 18 or above 40 years.

Other

  • A score in the severe or extremely severe range on any DASS-21 subscale, or any indication of suicidal thinking.
  • Inability to give informed consent or to comply with the study procedures.

Who the study is looking for

  • Aged between 18 and 40 years, the band Chen et al. (2024) identify as carrying the heaviest global burden of migraine prevalence and disability.
    • A neurologist's diagnosis of chronic migraine established in accordance with International Headache Society criteria.
    • A MIDAS total of 21 or above, so that participants carried a clinically meaningful level of impairment and had room to improve (Stewart et al., 2001).
    • A score in the mild to moderate band on at least one DASS-21 subscale, since the study concerned migraine-associated distress rather than primary psychiatric disorder (Lovibond \& Lovibond, 1995).
    • A stable prophylactic medication regimen for at least one month before enrolment, with no change planned during the study, so that any shift in outcome could not be laid at the door of a change in drugs.
    • Both men and women were eligible, so that the sample resembled the clinical population rather than one gender.
    • At least primary-level education, sufficient to read and complete the self-report instruments independently.
    • Enough Urdu or English to engage with the intervention material.
    • Willingness to give written informed consent and to commit to the full schedule of six weekly sessions and both assessment appointments.
    • Residence in Gujranwala for the duration of the study and reachable by telephone, so that attendance could be monitored and attrition kept down.
    • Not receiving any other form of psychotherapy at enrolment, so that the effect of the study interventions could be isolated.

Age in the registry: 18 years to 40 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
GIFT University
Coordinator of this site? Confirm its status
GujranwalaPakistanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.